RxDoctor Payments Data

Shelly Chandler, NP

Family · Milford, CTNPI 1629055736

Payments from drug & device makers

$735in general payments, 2019–2025

Across 31 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$169
  • Boehringer Ingelheim$110
  • Amgen$71
  • Mannkind Corporation$59
  • AbbVie$54
  • Lilly USA, LLC$54
  • plus $217 from 8 others

What the payments were for

  • Food & beverage$69394%
  • Education$436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$735 in reported general payments places this provider in the 65th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$30,454
Medicare patients
111
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$125,862
OzempicSemaglutide67$101,473
TrulicityDulaglutide52$54,914
JardianceEmpagliflozin46$54,574
RybelsusSemaglutide27$41,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,174
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$21,241
FarxigaDapagliflozin Propanediol23$20,749
TradjentaLinagliptin21$20,323
JanuviaSitagliptin Phosphate18$15,339
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$13,737
LinzessLinaclotide11$13,416
Tresiba Flextouch U-100Insulin Degludec21$12,530
Fiasp FlextouchInsulin Aspart (Niacinamide)11$9,526
GemtesaVibegron18$8,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$54$180,776165 claims
Novo NordiskOzempic, Rybelsus$169$143,21094 claims
Boehringer IngelheimJardiance, Tradjenta$110$74,89767 claims
AbbVieLinzess, Synthroid$54$15,42929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,596 family providers in Connecticut.

Other family in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →